49. Why Don’t We Have a Cure for Alzheimer’s?

49. Why Don’t We Have a Cure for Alzheimer’s?

Up next

The Economics of Everyday Things: Animal Urine

In the newest show from the Freakonomics Radio Network, host Zachary Crockett explores the hidden side of the things around us. This week: One creature’s trash is another’s cash. (Or, how one man found profit in pee.) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com ...  Show more

Tom Brady, A.D.H.D., and a Really Bad Headache (Bonus)

A sneak peek at Bapu's new book, Random Acts of Medicine, available now from Doubleday, and an announcement about the show. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. 

Recommended Episodes

What Causes Alzheimer's?
Distillations | Science History Institute

The human brain is mysterious and complicated. So much so, one might be tempted to argue that it only makes sense that we still don't have a cure for Alzheimer's disease, despite decades of research. But this isn't the whole story. We've partnered with Vox's Unexplainable< ...

  Show more

How Well Does A New Alzheimer's Drug Work For Those Most At Risk?
Short Wave

A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. It was the most diverse trial for an Alzheimer's treatment to date, but still not enough t ...  Show more

Alzheimer’s drug has experts divided; rising ICE use in Australia; the disappointing results of a study aimed at improving ovarian cancer survival rates
Health Report - Full program podcast

This week, the first of a new series on substance use and what you need to know about ICE - crystal meth. Does early diagnosis of ovarian cancer through screening make a difference to survival rates? And the search for an Alzheimer's disease treatment is as controversial as ever. ...  Show more

Controversial new Alzheimer's drug in the spotlight
Business Daily

After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ...  Show more